Clinical application of^(99m)Tc-labeled peptides for tumor imaging:Current status and future directions  

作　　者：Jiyun Shi Shuang Liu 

机构地区：[1]Key Laboratory of Biomacromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing,China [2]School of Health Sciences,Purdue University,West Lafayette,Indiana,USA

出　　处：《iRADIOLOGY》2024年第1期17-34,共18页融合影像学(英文)

基　　金：National Natural Science Foundation of China,Grant/Award Number:81971676。

摘　　要：Targeting receptors overexpressed on cancer cells with radiolabeled peptides has become a crucial aspect of molecular imaging in oncology.Small peptides offer favorable characteristics for tumor targeting with minimal side effects and toxicity owing to their small size and simple radiolabeling protocols.Among them,somatostatin analogs have received regulatory approval for the diagnosis and treatment of neuroendocrine tumors.Cyclic RGD(Arg-Gly-Asp)peptides,bombesin analogs,and glucagon-like peptide-1 analogs are currently under development and/or undergoing clinical trials.The most used radionuclides for tumor imaging include^(99m)Tc and ^(111)In for single-photon emission computed tomography,^(68)Ga and^(18)F for positron emission tomography.This review highlights the clinical potential and future prospects of^(99m)Tc-labeled peptides for tumor imaging.

关 键 词：^(99m)Tc radiolabeled peptides SPECT tumor imaging 

分 类 号：R73[医药卫生—肿瘤]